Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change
Sanofi’s interim leadership sought on a Thursday earnings call to quell concerns that its sudden defense of Dupixent’s patents had anything to do with the departure of CEO Paul Hudson.
Read the full article on the original site.
Read Full Article